ISSN 1004-4140
CN 11-3017/P
CHEN X Y, XU J C, LI Q Q, et al. The predictive value of CT findings in invasive behavior of pancreatic neuroendocrine tumors[J]. CT Theory and Applications, 2022, 31(3): 399-407. DOI: 10.15953/j.ctta.2021.082. (in Chinese).
Citation: CHEN X Y, XU J C, LI Q Q, et al. The predictive value of CT findings in invasive behavior of pancreatic neuroendocrine tumors[J]. CT Theory and Applications, 2022, 31(3): 399-407. DOI: 10.15953/j.ctta.2021.082. (in Chinese).

The Predictive Value of CT Findings in Invasive Behavior of Pancreatic Neuroendocrine Tumors

More Information
  • Received Date: December 24, 2021
  • Accepted Date: March 03, 2022
  • Available Online: March 14, 2022
  • Published Date: May 22, 2022
  • Objective: To explore the value of CT findings in predicting the invasive behaviors of pancreatic neuroendocrine tumor (pNET). Methods: The clinical data and CT data of 120 patients with pNET confirmed by surgical resection and pathology were retrospectively analyzed. Preoperative CT plain scan and enhanced examination of pancreas were performed. Image analysis included tumor location, shape, capsule, cystic change, calcification, pancreatic duct dilation and enhancement pattern. The maximum and minimum diameter of the tumor were measured. The CT value of the solid part of the tumor was measured in plain scan, arterial phase and portal vein phase. Enhancement difference in arterial phase and portal vein phase were calculated. The tumors were divided into invasive group and non-invasive group according to the pathological results. The difference of CT findings between the two groups was compared. Receivers operating characteristic (ROC) curves were drawn to evaluate the predictive value of tumor maximum diameter, minimum diameter, enhancement difference in arterial phase and portal vein phase on the invasive behavior of pNET. Results: There were no statistical differences in tumor location, pancreatic duct dilation, cystic change, calcification and enhancement pattern between the invasive and non-invasive groups. There were statistically significant differences between the two groups in the quantitative characteristics of the maximum diameter, the minimum diameter, enhancement difference in arterial phase and portal vein phase and the areas under ROC curve were 0.693, 0.69, 0.73 and 0.64, indicating discrimination efficiency. Multivariate Logistic regression analysis of 6 meaningful image features showed that arterial enhancement difference was an independent predictor of pNET invasive behavior, and the optimal critical point of arterial enhancement difference was 90.1HU (sensitivity 0.714, specificity 0.656, positive predictive value 64.5%, negative predictive value 72.4%, accuracy 68.3%). Conclusion <b<:</b< Large volume, irregular shape, incomplete or no capsule of pancreatic neuroendocrine tumor, and low enhancement difference of solid tumor components in arterial and portal phases suggested invasive behavior of tumor, and enhancement difference in arterial phase was an independent predictor of invasive behavior of pNET.
  • [1]
    吴文铭, 陈洁, 白春梅, 等. 中国胰腺神经内分泌肿瘤诊疗指南(2020)[J]. 中华外科杂志, 2021,59(6): 401−421. DOI: 10.3760/cma.j.cn112139-20210319-00135.

    WU W M, CHEN J, BAI C M, et al. The Chinese guidelines for the diagnosis and treatment of pancreatic neuroendocrine neoplasms (2020)[J]. Chinese Journal of Surgery, 2021, 59(6): 401−421. DOI: 10.3760/cma.j.cn112139-20210319-00135. (in Chinese).
    [2]
    敖炜群, 杨光钊, 王健, 等. 非典型胰腺神经内分泌肿瘤的影像学特征[J]. 中华胰腺病杂志, 2020,20(6): 458−461. doi: 10.3760/cma.j.cn115667-20200416-00054
    [3]
    XU W, YAN H, XU L, et al. Correlation between radiologic features on contrast-enhanced CT and pathological tumor grades in pancreatic neuroendocrine neoplasms[J]. The Journal of Biomedical Research, 2020, 35(3): 179−188. DOI: 10.7555/JBR.34.20200039.
    [4]
    OHKI K, IGARASHI T, ASHIDA H, et al. Usefulness of texture analysis for grading pancreatic neuroendocrine tumors on contrast-enhanced computed tomography and apparent diffusion coefficient maps[J]. Japanese Journal of Radiology, 2021, 39(1): 66−75. DOI: 10.1007/s11604-020-01038-9.
    [5]
    KANG J, RYU J K, SON J H, et al. Association between pathologic grade and multiphase computed tomography enhancement in pancreatic neuroendocrine neoplasm[J]. Journal of Gastroenterology and Hepatology, 2018. DOI: 10.1111/jgh.14139.
    [6]
    BELOUSOVA E, KARMAZANOVSKY G, KRIGER A, et al. Contrast-enhanced MDCT in patients with pancreatic neuroendocrine tumours: Correlation with histological findings and diagnostic performance in differentiation between tumour grades[J]. Clinical Radiology: Journal of the Royal College of Radiologists, 2017, 72(2): 150−158. DOI: 10.1016/j.crad.2016.10.021.
    [7]
    BICCI E, COZZI D, FERRARI R, et al. Pancreatic neuroendocrine tumours: Spectrum of imaging findings[J]. Gland Surgery, 2020, 9(6): 2215−2224. DOI: 10.21037/gs-20-537.
    [8]
    PENITENTI F, LANDONI L, SCARDONI M, et al. Clinical presentation, genotype-phenotype correlations, and outcome of pancreatic neuroendocrine tumors in Von Hippel-Lindau syndrome[J]. Endocrine, 2021, 74(1): 180−187. DOI: 10.1007/s12020-021-02752-8.
    [9]
    YANG M, TIAN B, ZHANG Y, et al. Epidemiology, diagnosis, surgical treatment and prognosis of the pancreatic neuroendocrine tumors: Report of 125 patients from one single center[J]. Indian Journal of Cancer, 2015, 52(3): 343−349. DOI: 10.4103/0019-509X.176746.
    [10]
    LI W X, MIAO F, XU X Q, et al. Pancreatic neuroendocrine neoplasms: CT spectral imaging in grading[J]. Academic Radiology, 2021, 28(2): 208−216. DOI: 10.1016/j.acra.2020.01.033.
    [11]
    OKABE H, HASHIMOTO D, CHIKAMOTO A, et al. Shape and enhancement characteristics of pancreatic neuroendocrine tumor on preoperative contrast-enhanced computed tomography may be prognostic indicators[J]. Annals of Surgical Oncology, 2017, 24(5): 1399−1405. DOI: 10.1245/s10434-016-5630-4.
    [12]
    CANELLAS R, BURK K S, PARAKH A, et al. Prediction of pancreatic neuroendocrine tumor grade based on CT features and texture analysis[J]. American Journal of Roentgenology, 2018, 210(2): 341−346. DOI: 10.2214/AJR.17.18417.
    [13]
    GAO H, WANG W, ZHANG W, et al. The distinctive characteristics of the micro-vasculature and immune cell infiltration in cystic pancreatic neuroendocrine tumors[J]. Journal of Endocrinological Investigation, 2021, 44(5): 1011−1019. DOI: 10.1007/s40618-020-01396-1.
    [14]
    JAYSON G C, KERBEL R, ELLIS L M, et al. Antiangiogenic therapy in oncology: Current status and future directions[J]. Lancet, 2016, 388(10043): 518−529. DOI: 10.1016/S0140-6736(15)01088-0.
    [15]
    CHU X, GAO X, JANSSON L, et al. Multiple microvascular alterations in pancreatic islets and neuroendocrine tumors of a Men1 mouse model[J]. American Journal of Pathology, 2013, 182(6): 2355−2367. DOI: 10.1016/j.ajpath.2013.02.023.
    [16]
    WORHUNSKY D J, KRAMPITZ G W, POULLOS P D, et al. Pancreatic neuroendocrine tumours: Hypoenhancement on arterial phase computed tomography predicts biological aggressiveness[J]. The Official Journal of the International Hepato Pancreato Biliary Association, 2014, 16(4): 304−311. DOI: 10.1111/hpb.12139.

Catalog

    Article views (206) PDF downloads (21) Cited by()
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return